Eng Hooi (Cheryl) Tan
BSc (Pharm), MPH, PhD
Postdoctoral Research Assistant in Pharmaco-epidemiological Methods
As a pharmacoepidemiologist, I apply methods to investigate the drug utilisation and comparative effectiveness and safety of medications using routinely collected healthcare data. I am currently involved in a study to assess the comparability of osteoporosis treatment groups via negative control outcomes analysis. I hope to support reliable evidence generation that translates into better patient care.
I completed my PhD at the National University of Singapore (NUS). My thesis explored the detection of drug-induced liver injury in electronic medical records. I obtained my Master of Public Health (MPH) from the University of Sydney and graduated from NUS with a BSc (Pharmacy) as an ASEAN scholar.
My working experience includes practicing as a pharmacist in a tertiary hospital and an oncology centre. While working on my PhD, I was also a research associate managing a randomised controlled trial evaluating the use of SMS reminders to improve medication adherence in women with breast cancer.
I joined NDORMS in June 2020.
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.
Tan EH. et al, (2021), Rheumatology (oxford)
Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.
Prieto-Alhambra D. et al, (2021), Res sq
Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy.
Tan EH. et al, (2021), J health psychol
Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain
Roel E. et al, (2021)
Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis.
Tan EH. et al, (2020), Medrxiv